About Careers MedBlog Contact us

Do 'Death Cap' Mushrooms Have Therapeutic Qualities to Treat Colorectal Cancer?

by Mansi Shroff on April 24, 2015 at 10:50 AM
Font : A-A+

Do 'Death Cap' Mushrooms Have Therapeutic Qualities to Treat Colorectal Cancer?

The "death cap" mushrooms, scientists reveal, is a possible cure to treating colorectal cancer. Though cancer scientists have considered toxin, alpha-amanatin derived from the fungus, as a possible cancer treatment, due to its penchant for causing liver toxicity, its potential as an effective therapy has been limited.

Now, researchers at The University of Texas MD Anderson Cancer Center looked at antibody drug conjugates (ADCs) based on alpha-amanatin as one solution. They found that ADCs, when aimed at a gene called POLR2A, are highly effective in mouse studies in treating colorectal cancer. The drug caused complete tumor regression and greatly reduced toxicity. ADCs allow for improved targeting of cancer cells, resulting in less impact on healthy cells.


The study by Xiongbin Lu, Ph.D., associate professor of Cancer Biology, observed that when the common tumor suppressor gene, TP53 is deleted resulting in cancer growth, another nearby gene, POLR2A is also deleted. Normal cells have two copies of POLR2A and TP53 genes. Lu targeted cancers that had a single copy of both genes, representing 53 percent of colorectal cancers, 62 percent of breast cancers and 75 percent of ovarian cancers.

Lu said that POLR2A was an essential gene for cell survival, including cancer cells. Because there was only one copy, the cancer cells become more susceptible to suppression of this gene.

Discovering that POLR2A is deleted at the same time as TP53 meant that therapies could more narrowly target the genetic processes allowing cancer cells to thrive.

Understanding that one copy of POLR2A could allow cancer to grow gives researchers a new target to hit. As it turned out, it could be suppressed by an ADC based on the mushroom toxin. Lu's team tested the drug, alpha-amanatin as it was believed that it specifically inhibited POLR2A.

Lu said they found that suppression of POLR2A with low-dose alpha-amanatin stopped cancer cell growth and reduced toxicity.

The study was published in Nature.

Source: Medindia


Recommended Reading

Latest Cancer News

How Do Neutrophils Impact Pancreatic Cancer Treatment Resistance?
A nanoengineering platform targets neutrophils, the white blood cells without killing pancreatic cancer cells paving the way for effective treatments.
Lung Cancer: The Survival Advantage of Lobectomy Over Wedge Resection
The survival rates between lobectomy and wedge resection surgical procedures were found to be the same among lung cancer patients.
Could TKI Cancer Drugs Lead to Inflammatory Side Effects?
The mechanism by which the kinases cause inflammation has been discovered by scientists.
Are Biomarkers the Key to Identifying Early Pancreatic Risk?
Pancreatic cancer cases are on the rise. The biomarker approach could reduce the chance of developing pancreatic cancer.
How Do New Drugs Work Together to Reduce Lung Tumors?
New combination of medications trametinib and entinostat were found to decrease lung cancer in mice.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Do 'Death Cap' Mushrooms Have Therapeutic Qualities to Treat Colorectal Cancer? Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests